此次公司盐酸文拉法辛原料药的获批上市，标志着公司具备了在国内市场的销售资格，拓宽了公司在抗抑郁治疗领域的产品管线，有助于进一步拓展公司原料药业务，进一步推进做精原料的业务发展战略，对公司未来发展具有一定的积极意义。Apeloa Pharmaceutical (000739.SZ) announced that recently, the company's wholly-owned subsidiary Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd.
According to Zhito Finance APP, Apeloa Pharmaceutical (000739.SZ) announced that recently, its wholly-owned subsidiary Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd. ("Jiayuan Pharmaceutical") received the approval notice issued by the National Medical Products Administration ("NMPA") for the marketing application of venlafaxine hydrochloride active pharmaceutical ingredient.
It is reported that venlafaxine is a norepinephrine and serotonin reuptake inhibitor, primarily used in clinical practice to treat various types of depression and generalized anxiety disorder, especially suitable for depression accompanied by anxiety.
The approval of the marketing of venlafaxine hydrochloride active pharmaceutical ingredient marks that the company has obtained the sales qualification in the domestic market, broadening the company's product pipeline in the field of anti-depressant treatment, which helps further expand the company's active pharmaceutical ingredient business and advance the global strategy for refining the active pharmaceutical ingredient business development, having certain positive significance for the company's future development.
